Abstract
Lipids are a heterogenous class of molecules involved in signaling, cell structure and energy storage. Lipid metabolism is dysregulated in aging and aging-related diseases such as cancer, metabolic disorders, and neurodegeneration. In this study, we developed a biological age predictor – a Lipid Aging Clock - based on human serum lipidome data of pancreatic ductal adenocarcinoma (PDAC) patients, that has a Pearson correlation coefficient of 0.81 to chronological age with a median absolute error of 4.5 years. This shows that it is possible to build aging clocks measuring aging from pathological cohorts.
We find that LipidAgeAcceleration is increased in both PDAC and pancreatitis, indicating that these pancreatic conditions accelerate aging or that individuals with age acceleration or more likely to acquire them (or both). Furthermore, the lipid age clock is predictive of PDAC survival, where positive accelerated Lipid Age is associated with an 86% higher mortality risk. Among the lipid species associated with LipidAgeAcceleration, Ceramides, Sphingomyelins and Glycerophosphocholines, have statistically significant hazard ratios, and directly impact increased mortality. Pathway analysis of lipid species selected by the lipid clock further identifies age-dependent dysregulation of specific lipid pathways, including Sphingolipid, Glycerolipid, Glycerophospholipid metabolism, and steroid biosynthesis. Sphingolipid metabolism is significantly dysregulated in both aging and PDAC, connecting aging dynamics and cancer mortality. Moreover, sphingolipids are involved in inflammatory processes, and therefore the lipid aging clock could be, at least in part, reflecting inflammaging and is likely influenced by age-related alterations to the immune system. In summary, our work shows that lipid alterations are a robust biological age predictor with utility in cancer and aging research, as well as in predicting disease-associated outcomes.
Competing Interest Statement
Maximilian Unfried: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Amaury Cazenave-Gassiot: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Evelyne Bischof: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Michal Holcapek: M.H. is listed as an inventor on patent EP 3514545 related to this work. Morten Scheibye-Knudsen: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Markus R. Wenk: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Jan Gruber: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Brian K. Kennedy: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Funding Statement
Maximilian Unfried was funded through the SINGA scholarship. Work at HLTRP was supported by NUHSRO/2020/114/Rethinking old drugs/BKK LOA - Rethinking old drugs and natural products for ageing and related diseases. Work at SLING is supported by grants from the National University of Singapore via the Life Sciences Institute (LSI), and the National Research Foundation and A*STAR IAF-ICP I1901E0040
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data from this paper https://www.nature.com/articles/s41467-021-27765-9#Sec25
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
All the data is uploaded on github at https://github.com/max-unfried/lipid-clock/
